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Adipose-derived stem cells for treatment of
chronic ulcers: current status
Jens Selch Holm1*, Navid Mohamadpour Toyserkani2 and Jens Ahm Sorensen1
Abstract
Chronic ulcers remain a difficult challenge in healthcare systems. While treatment options are limited, stem cells may
be a novel alternative. Adipose-derived stem cells (ADSC) have become increasingly popular compared with bone
marrow-derived stem cells as they are far easier to harvest. To summarize the current status of treating chronic ulcers
with ADSC, this systematic review includes all clinical trials on the subject from PubMed and EmBase, as well as all
registered clinical trials on ClinicalTrials.Gov. A total of nine clinical trials and fourteen registered trials were included.
The studies were significantly different in terms of study design and patient population, and the overall quality of the
studies was low to moderate. Despite the overall low study quality and the significant differences between the studies,
some conclusions were consistent: ADSCs are safe, improve the healing of chronic ulcers, and reduce pain. As these
results are consistent despite the shortcomings of the studies, they appear to highlight the efficacy of ADSCs in the
treatment of chronic ulcers. Larger numbers of higher quality studies are needed to determine the precise role of
ADSCs in treating chronic leg ulcers.
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Background
Chronic leg ulcers (CLU) are a common and compli-
cated disease to treat [1], and result in high morbidity
[2] and significantly reduced quality of life [3]. Normal
wound healing consists of four overlapping phases:
hemostasis, inflammation, proliferation, and remodeling
[4]. Most ulcers heal when the cause is eliminated and
the ulcer is treated with standard wound care. Some ul-
cers, however, are for various reasons locked in the in-
flammatory stage and do not heal [5]. Regarding CLUs,
most of the ulcers are caused by venous insufficiency or
arterial ischemia, often secondary to diabetes, but some
CLUs do not have an apparent underlying condition [6].
CLUs are a challenge for the physician, a significant
physical and psychological setback for the patient, and a
heavy burden on the healthcare systems. Thus, an
American study reported an average cost of treating
chronic venous leg ulcers of $9685 per patient per year
[7]. This reflects that these patients are difficult to treat,
as the available treatment options are limited, leaving
patients with a chronic condition severely affecting their
quality of life. CLUs result in substantial use of the re-
sources of healthcare systems regarding materials, hos-
pital appointments, reduced working capability for the
patients, and impairment of the patient in general [8].
Treatment with stem cells might be a new treatment op-
tion for these patients. Stem cells [9] have the potential to
differentiate into numerous types of cells [10]. Over the
last decade, stem cell therapy has shown great potential in
the treatment of a variety of different conditions, such as
orthopedic disorders, inflammatory diseases, hepatic fail-
ure, and autoimmune disorders [11, 12]. At the time of
writing, adverse events have not been reported; therefore,
stem cell treatment is currently regarded as safe [13]. A
review [14] including more than 1400 patients found a fa-
vorable safety profile of adipose-derived stem cells
(ADSC), but also highlighted the poor quality of most
studies in regard to registering adverse events.
Adipose tissue is an excellent source of autologous ADSC
and can be harvested easily compared with bone marrow-
derived stem cells (BMSC) [15]. Adipose tissue has in re-
cent years surpassed bone marrow as the preferred source
of mesenchymal stem cells [16]. Besides being abundant,
far easier to harvest, and with a lower risk of complications
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for the patient, adipose tissue additionally contains about
40 times more stem cells than bone marrow [17]. A simple
liposuction of the abdomen or inner thigh performed under
local or general anesthesia is sufficient to harvest the re-
quired number of ADSC without any significant risk of
complications [18]. ADSC can be either freshly isolated or
cultured. The culturing takes several days or weeks, and
cannot be performed as a same-day procedure.
Stem cells are a heterogeneous pool of cells with numer-
ous capabilities [19]. They possess anti-inflammatory and
neoangiogenic effects, secrete numerous growth factors,
and can differentiate into various cells types [20]. Many of
these are known to be involved in the complex healing of
wounds [21], although the exact capabilities and mecha-
nisms of action of stem cells in wound healing are not yet
fully understood. Research suggests that stem cells work
though two mechanisms of action: firstly they attenuate
the general inflammatory response and, secondly, they
transform into cells involved in wound healing such as fi-
broblasts, myofibroblasts, antigen presenting cells, endo-
thelial progenitor cells, and so forth [22].
Freshly isolated ADSC are far more heterogeneous
compared with the quite homogeneous cells harvested
from cultured ADSC [23]. The greater variety of cell
types in the freshly isolated ADSC could have a signifi-
cant advantage in wound healing, compared with the far
more limited number of different cells in cultured
ADSC. In ADSC, endothelial, hematopoietic, and pericy-
tic lineages represent 10–20%, 25–45%, and 3–5%, re-
spectively, of the total nucleated cells.
Several methods of isolating ADSC have been reported
[16, 24]. The most common is enzymatic isolation. Some
techniques use simple centrifugation and vibration to iso-
late a stem cell pellet. Others are more complex and
involve, for example, enzymatic (collagenase) dissolving of
the adipose tissue. Fully automatic systems also exist. The
different methods have advantages and disadvantages
regarding the time required for the procedure, the need
for advanced equipment/specially trained personnel, and
financial cost. Data describing the efficacy of various
methods are not available; therefore, no standardized
method exists [25]. In addition, the optimal method of
application of ADSC is still undecided.
Various animal studies have documented the positive ef-
fect of ADSC in accelerating healing of chronic ulcers
[19]. The clinical translation is ongoing, with several clin-
ical studies already published. The aim of this review is to
describe the available data on the treatment of CLU with
autologous ADSC by identifying published human studies
and ongoing/registered clinical trials on the matter.
Data acquisition
To identify the relevant clinical trials, a search was per-
formed on PubMed and EmBase for all human studies in
English on ADSC in the treatment of chronic ulcers (Fig. 1)
according to the PRISMA statement [26]. The search was
performed in December 2017 independently by both the
first and second author of this article by using the search
terms: (“adipose-derived stem cells” OR “adipose stem cells”
OR “stromal vascular fraction” OR “mesenchymal cells” OR
“stromal cells”) AND (“wound healing” OR “ulcer”). Arti-
cles from 1 January 1995 to December 2017 were included.
A similar search was performed on EmBase.
In total, 3404 articles were identified after duplicates
were removed (n = 956) using Covidence [27]. The titles
and abstracts were screened, and 3352 articles not rele-
vant to the subject were excluded, leaving 52 articles
that were potentially relevant and the full articles were
obtained for further review. Of these, 43 studies were ex-
cluded (see Fig. 1 for more detail) and a total of nine
clinical studies were identified and included in the re-
view (Table 1). Their reference lists were evaluated
manually for additional studies. Author/year, title, cause
of ulcer, patient population, study design, type of ADSC,
application method, primary endpoints, follow-up dur-
ation, and conclusions were recorded from the included
studies. For a full overview of the results, see Table 1.
To identify past, ongoing, or future registered studies
on ADSC in the treatment of chronic ulcers, a thorough
search of ClinicalTrials.gov was performed. Using the
search terms “stem cells” or “adipose” or “stromal cells”
in combination with “ulcer” or “wound”, a total of four-
teen studies were identified (Table 2).
Study title, type of ADSC and application method,
study design, cause of ulcer, trial institution, NCT num-
ber, duration period, and study status were recorded.
Results
Published clinical studies
The clinical trials included in the review were: study 1,
Han et al. [28]; study 2, Kirana et al. [29]; study 3,
Marino et al. [30]; study 4, Bura et al. [31]; study 5,
Raposio et al. [32]; study 6, Carstens et al. [33]; study 7,
Chopinaud et al. [34]; study 8, Konstantinow et al. [35];
and study 9, Darinskas et al. [36].
The data were collected as described in the Data ac-
quisition section; for the full overview of the included
studies and data, refer to Table 1.
Cause of chronic ulcers
All studies except study 3 included patients with periph-
eral artery disease (PAD). PAD was primarily a compli-
cation to diabetes (studies 1, 2, 6, 7, 8, and 9),
thromboangiitis obliterans (study 5) or primary athero-
sclerosis (study 4). Studies 3 and 4 included patients
with hypertensive and venous ulcers. Study 3 had only
hypertensive/venous ulcers, whereas study 4 had 45%
hypertensive/venous ulcers. Study 8 included 16 patients
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of which nine had arterial-venous disease and seven pa-
tients with venous disease.
Study design
The studies varied significantly in study design. No studies
were blinded and only studies 1 and 5 were randomized.
Three studies (1, 3, and 5) had control groups. The size of
the groups ranged from 7 to 28 patients in the case groups
and from 0 to 28 patients in the control groups, and the
total number of patients included ranged from 7 to 54
patients. The follow-up period varied from 2 months
(study 1) to 18 months (studies 5 and 6).
Type of ADSC
Different types of stem cells were used in the studies.
Freshly isolated stem cells were used in studies 1, 3, 5, 6,
7, 8, and 9, and cultured cells were used in studies 2 and
4. All studies used adipose tissue harvested from the ab-
domen or inner thigh using liposuction.
Studies 1 and 6 isolated an ADSC pellet using collage-
nase and centrifugation. Studies 2 and 4 used cultured
stem cells digested with collagenase and centrifuged. In
study 3, a Celution 800® system isolated the ADSC. In
study 5, e-PRP (platelet-rich plasma combined with
ADSC isolated using vibration and centrifugation) was
the type of ADSC investigated. Study 7 isolated the
ADSC with the LipoStructure® [37] technique. Study 8
isolated the ADSC with the Transpose RT™ Processing
Unit (TPU; InGeneron Inc., Houston, TX, USA).
Study 9 investigated uncultured ADSC isolated
without collagenase using mechanical isolation (the fat
was minced using a metal mill and subsequently
centrifuged).
Application method
The application method varied from study to study.
Topical application of the stem cells onto the wound
was performed in study 1. Studies 2, 4, 6, and 9 injected
the ADSC intramuscularly. In study 3, the stem cells
were injected around the ulcer and, in studies 5 and 7,
the stem cells were injected into and around the ulcer.
Study 8 injected the ADSC into and around the ulcer,
but also applied 2.5 mL of ADSC onto a sponge which
was fixed on top of the ulcer.
Ulcer healing
All studies reported healing of the chronic ulcers to
varying degrees. The results reported were:
Fig. 1 Search flow diagram. ADSC, adipose-derived stem cells; RCT, randomized controlled trial
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– Study 1: 100% healing of the case group compared
with 62% in the control group.
– Study 2: 66.7% of the chronic ulcers had healed at
6 months.
– Study 3: Six out of ten patients in the case group
had total healing of the ulcer versus none in the
control group.
– Study 4: A decrease in the number of ulcers and in
ulcer size in all patients, except two patients where
amputation was performed.
– Study 5: Reported similar total ulcer healing rates
between the case and the control group (71% vs
68%), but a significantly higher wound closing rate
in the case group (0.2287 cm2/day vs 0.0890 cm2/day,
p = 0.0257).
– Study 6: Four of six wounds closed within 9 months.
Regarding the remaining two patients, one patient
had a wound in the granulation stage when she died
of unrelated cardiac arrest at 4 months and the
other patient had a successful skin graft to close the
wound at 5 months, where the ulcer was in the
granulation stage.
– Study 7: A 73.2% median closure rate at 3 months
and 93.1% at 6 months.
– Study 8: All venous ulcers and four of nine arterial-
venous ulcers healed. Complete wound closure was
achieved within 9 to 26 weeks of ADSC treatment.
– Study 9: Seven patients with ulcers. All ulcers
healed, although two patients required major
amputation after which the amputation sites healed.
Study conclusions
The overall quality of the studies is low to moderate.
The patient populations are limited in size and only a
few studies are randomized. The lack of blinding in all
studies as well as the limited randomization significantly
increases the risk of bias. Quadruple blinding, larger
study populations, matched control groups, and more
homogenous studies would significantly improve the
current research. Basic research investigating optimal
dosage of stem cells and the administration route is also
lacking.
Despite the shortcomings in terms of quality of the
studies, and the studies being heterogeneous, some con-
clusions are consistent:
1) No studies report any adverse event of significance,
if any at all.
2) In all studies examining wound-related pain, they
all found a reduction in the sensation of pain fol-
lowing stem cell treatment (studies 2, 3, 4, 6, 7, 8,
and 9).
3) All studies showed noteworthy progress in the healing
of the chronic ulcers. In the studies with control
groups, a significantly higher healing rate of the case
groups compared with the control groups was seen.
Registered clinical trials
All relevant clinical trials registered on www.Clinical-
Trials.gov were included (in total fourteen studies; see
Table 2 for full overview of the studies).
Status
A few studies were completed, and the results published
(studies A and E), while most were either ongoing (C, H,
I, J, and L), not yet recruiting patients (K, M, and N) or
have exceeded the anticipated completion date consider-
ably without an update for years (B, D, F, and G).
Study design
The study design varies from study to study. Studies B,
C, G, H, I, and L are randomized, but only study I and B
are blinded. Studies B, C, H, I, and L have control
groups. Estimated enrollment of patients ranges from 9
(J) to 250 (B). The follow-up period ranges from
3 months (A, F, and H) to 12 months (B, C, L, and M).
Cause of chronic ulcers
Several causes of ulcers are included in the studies.
Critical limp ischemia (A, C, G, and J), diabetic foot ul-
cers (D, K, and M), pressure ulcer (I), chronic venous
stasis ulcers (L), and hypertensive ulcers (E) were the
diagnoses involving a single underlying condition. Study
B includes both diabetic and venous ulcers and studies
D and H include diabetic foot ulcers and lower limp is-
chemia. Study J examines critical limp ischemia, throm-
boangiitis obliterans, and diabetic foot ulcers. Study F
includes chronic wounds without further specification.
Type of ADSC
Most studies utilize autologous ADSC from lipoaspirate
without further specification (studies A, C, D, E, F, G, H,
I, K, M, and N). However, study B uses autologous
lipoaspirate with no further ADSC isolation, study J uses
ADSC extracted by enzymatic digestion, study L isolates
the ADSCs using the Transpose® RT System, and study
M involves stem cells seeded in curcumin-loaded chito-
san nanoparticles into collagen-alginate.
Application method
Intramuscular injection is planned for studies A and J. In-
jection into or around the wound is planned in studies B,
F, H, K, L, and N. Study C involves intra-arterial adminis-
tration of the stem cells. In study I, the ADSC are injected
into a fibrin sealant and applied to the wound. Studies D,
E, and M do not explain how the stem cells are planned
to be applied. Study G applies intravenous and intramus-
cular injection versus intramuscular injection only.
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Summary
As in the published clinical studies in this field, the reg-
istered clinical studies differ significantly. No consistency
was observed across isolation technique, application
method, or dose of ADSC. Furthermore, several different
causes of ulcer are being investigated and the study
designs are different. A few of the studies have been
published, some are ongoing, but some of the studies
have surpassed their estimated completion date and the
status is unknown. Whether these studies will ever be
completed/published remains questionable. Not all on-
going clinical trials are necessarily registered on Clinical-
Trials.gov, however, and there is no doubt that a
considerable amount of research in this field is currently
being conducted, and probably even more clinical trials
than the registered trials are currently being conducted.
Discussion
This systematic review concludes that current clinical
studies report that ADSC are safe, improve the healing
of chronic ulcers, and reduce pain. Interestingly, these
findings are consistent despite the overall poor study
quality, with a risk of significant bias and major diversity
between the studies regarding study design, underlying
conditions, methods of isolation, and methods of appli-
cation. This finding might show that ADSC have a sig-
nificant effect on chronic wounds of many etiologies and
are not particularly dependent on isolation and adminis-
tration techniques. On the other hand, one could argue
that the effect seen is caused by the substantial risk of
bias and not by the effect of the stem cells.
The published studies, as well as the ongoing studies,
on the subject are all diverse in study design. This is be-
cause several key questions remain unanswered in the
field of autologous ADSC in the treatment of chronic ul-
cers: What method of isolating ADSC is superior? What
conditions can be treated? Which application method is
best? What amount of stem cells is needed? To answer
these questions, large blinded and randomized studies as
well as additional basic research on the biology and cap-
abilities of stem cells are needed. High-quality blinded,
randomized studies in this field are still lacking, al-
though a few appear to be ongoing. A significant amount
of research in this field appears to be ongoing. Further
studies, however, are needed to define the long-term
safety and efficacy of ADSC.
In summary, BMSC and ADSC appear to have a posi-
tive effect on the healing of chronic wounds [38]. A sys-
tematic review and meta-analysis of BMSC in treatment
of chronic leg ulcers [39] found that BMSC, like ADSC,
are both safe and efficient. BMSC and ADSC seem to be
alike in terms of differentiation capacities and immune-
modulatory properties [40]. If this is true, ADSC would
inarguably be the preferred type of stem cell due to the
less invasive harvesting procedure needed to obtain
them and the abundance of fat for harvesting compared
with bone marrow. BMSC thus have no apparent advan-
tages over ADSC. Automatic closed systems have now
enabled ADSC treatment to be a fast and safe same-day
procedure, making the treatment favorable but also
costly. The high financial cost of standard chronic
wound care means that, although stem cell treatment is
expensive, it might be cheaper in the long-term and can
potentially save society a substantial amount of re-
sources if able to heal the chronic wound compared with
life-long wound care. Some low-quality studies [41] re-
port an effect of simply transplanting fat without isola-
tion of the stem cells, which could be an alternative
treatment option if resources are limited.
A limit to this study is the diversity of the studies in-
cluded. The number of clinical trials in this field is still
limited. Definitive conclusions on the matter are not
possible, as large studies with high quality and low risk
of bias are needed.
Conclusion
In conclusion, ADSC appear to be safe and have a posi-
tive effect on the healing of chronic ulcers. Treatment
options for chronic ulcers are currently extremely lim-
ited and few new treatments are under development.
Treatment with ADSC, however, is a novel and very ex-
citing new treatment for chronic ulcers and might soon
earn a pivotal role in this treatment; future studies will
define exactly what that role will be.
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